Search Result

Results for "

tumor microenvironment

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) ADC Linker (1) Adenosine Receptor (1) Akt (2) Apoptosis (11) Autophagy (3) Bcl-2 Family (1) c-Fms (1) CCR (3) CD73 (1) Checkpoint Kinase (Chk) (1) Complement System (1) COX (2) CTLA-4 (1) CXCR (1) Drug-Linker Conjugates for ADC (2) Endogenous Metabolite (3) Fluorescent Dye (1) HSP (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Ligands for E3 Ligase (1) Microtubule/Tubulin (1) MMP (1) Molecular Glues (1) Monocarboxylate Transporter (1) mTOR (2) NF-κB (1) NKCC (1) Parasite (4) PARP (1) PD-1/PD-L1 (4) PDGFR (1) PDHK (1) PI3K (1) PKD (1) Protein Arginine Deiminase (1) Reactive Oxygen Species (2) STAT (1) STING (2) Toll-like Receptor (TLR) (4)
By Research Areas:	Cancer (46) Endocrinology (1) Infection (4) Inflammation/Immunology (11) Metabolic Disease (2) Neurological Disease (2)

By Targets:

TNF Receptor (1)

ADC Linker (1)

Adenosine Receptor (1)

Akt (2)

Apoptosis (11)

Autophagy (3)

Bcl-2 Family (1)

c-Fms (1)

CCR (3)

CD73 (1)

Checkpoint Kinase (Chk) (1)

Complement System (1)

COX (2)

CTLA-4 (1)

CXCR (1)

Drug-Linker Conjugates for ADC (2)

Endogenous Metabolite (3)

Fluorescent Dye (1)

HSP (1)

Indoleamine 2,3-Dioxygenase (IDO) (3)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Ligands for E3 Ligase (1)

Microtubule/Tubulin (1)

MMP (1)

Molecular Glues (1)

Monocarboxylate Transporter (1)

mTOR (2)

NF-κB (1)

NKCC (1)

Parasite (4)

PARP (1)

PD-1/PD-L1 (4)

PDGFR (1)

PDHK (1)

PI3K (1)

PKD (1)

Protein Arginine Deiminase (1)

Reactive Oxygen Species (2)

STAT (1)

STING (2)

Toll-like Receptor (TLR) (4)

By Research Areas:

Cancer (46)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (11)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131347

PD-1/PD-L1-IN-NP19	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC₅₀ of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects .

HY-P990042

Gotistobart ONC-392; BNT 316	CTLA-4	Cancer
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .

HY-139245

MC-Ala-Ala-Asn-PAB	ADC Linker	Cancer
MC-Ala-Ala-Asn-PAB is a linker extracted from patent CN104147612A, page 14. MC-Ala-Ala-Asn-PAB can be used to synthesis the tumor microenvironment specific activated micromolecular targeted conjugate .

HY-154850

F-CRI1	STING	Cancer
F-CRI1 is a potent STING agonist with a K_d value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment .

HY-151559

Zn-DPA-maytansinoid conjugate 1	Checkpoint Kinase (Chk) STAT CXCR CCR	Cancer
Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an “inflamed hot tumor” .

HY-154869

PD-1/PD-L1-IN-34	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment .

HY-157157

PAD4-IN-3	Protein Arginine Deiminase	Cancer
PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .

HY-135748

Polyinosinic-polycytidylic acid sodium 10+ Cited Publications Poly(I:C) sodium	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis .

HY-134958

Polyinosinic-polycytidylic acid potassium Poly(I:C) potassium	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis .

HY-160053

Gint4.T aptamer sodium	PDGFR	Cancer
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

HY-146215

IDO1-IN-20	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
Hy-146215 is an enzyme that catalyzes the oxidative metabolism of tryptophan. It can immunosuppress tumors in the tumor microenvironment.

HY-161248

E7130	Microtubule/Tubulin	Cancer
E7130 is a microtubule inhibitor, which ameliorates the tumor microenvironment through suppression of cancer-associated fibroblasts (CAF) and promotion of tumor vasculature remodeling .

HY-148494

Tivumecirnon FLX475	CCR	Cancer
Tivumecirnon (FLX475) is an orally active CCR4 antagonist that blocks regulatory T cells from entering the tumor microenvironment, thereby reducing their interference with effective anti-tumor immune responses. Tivumecirnon has antitumor activity .

HY-116071

Autophagy-IN-3	Autophagy	Cancer
Autophagy-IN-3 (Compound 6k) is an autophagy inhibitor. Autophagy-IN-3 promotes metabolic stress in the tumor microenvironment and enhances the effects of cytostatics in combined treatments .

HY-D0067

7ACC1 5+ Cited Publications DEAC; Coumarin D 1421; D 1421	Monocarboxylate Transporter	Cancer
7ACC1(DEAC; Coumarin D 1421; D 1421) selectively interfere with lactate fluxes in the lactate-rich tumor microenvironment; inhibits lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters.

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-163146

TME-HYM (PH Probe)	Fluorescent Dye	Cancer
TME-HYM (PH Probe) is a novel fluorescent probe based on acidic tumor microenvironment (TME) activation and organic anion transporting polypeptide (OATPs, overexpressed on cancer cells), and can be selective uptaken. TME-HYM (PH Probe) can selectively lit up cancer cells and tumor tissues, offering dual tumor selectivity for precise visualization of tumor mass .

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-147204

Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE (compound S6) is a potent anticancer agent, which can be specific activated by tumor microenvironment. Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE can suppress tumor growth in mice (extracted from patent CN104147612A) .

HY-P99039

Oleclumab MEDI9447	CD73	Cancer
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .

HY-160421

TREM2-IN-1	Others	Inflammation/Immunology Cancer
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 is capable of relieving immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency .

HY-137206

ALV2	Ligands for E3 Ligase Molecular Glues	Cancer
ALV2 is a potent and selective Helios degrader. ALV2 binds CRBN, with an IC₅₀ of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable T_reg cell phenotype in the inflammatory tumor microenvironment .

HY-16938

5'-Methylthioadenosine 3 Publications Verification 5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine	Endogenous Metabolite Apoptosis Parasite	Metabolic Disease Cancer
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .

HY-130117

AlbA-DCA	Reactive Oxygen Species Apoptosis	Cancer
AlbA-DCA is a conjugate formed by the attachment of Albiziabioside A (AlbA) to a dichloroacetate acid (DCA) subunit. AlbA-DCA can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in tumor microenvironment (TME), and also selectively kills cancer cells and induce apoptosis .

HY-Y0445A

Sodium dichloroacetate Maximum Cited Publications 14 Publications Verification	PDHK Reactive Oxygen Species NKCC Apoptosis	Cancer
Sodium dichloroacetate is a metabolic regulator in cancer cells' mitochondria with anticancer activity. Sodium dichloroacetate inhibits PDHK, resulting in decreased lactic acid in the tumor microenvironment. Sodium dichloroacetate increases reactive oxygen species (ROS) generation and promotes cancer cell apoptosis. Sodium dichloroacetate also works as NKCC inhibitor .

HY-15888

PTC-209 5+ Cited Publications	Autophagy	Cancer
PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment .

HY-16938S

5'-Methylthioadenosine-13C6 -(Methylthio)-5'-deoxyadenosine-¹³C₆; 5'-Deoxy-5'-(methylthio)adenosine-¹³C₆; 5'-S-Methyl-5'-thioadenosine-¹³C₆	Endogenous Metabolite Apoptosis	Metabolic Disease Cancer
5'-Methylthioadenosine- ¹³C₆ is the ¹³C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].

HY-128946

CL2A-SN-38 1 Publications Verification	Drug-Linker Conjugates for ADC	Inflammation/Immunology Cancer
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .

HY-16938S1

5'-Methylthioadenosine-d3 5'-(Methylthio)-5'-deoxyadenosine-d₃; 5'-Deoxy-5'-(methylthio)adenosine-d₃; 5'-S-Methyl-5'-thioadenosine-d₃	Apoptosis Parasite Endogenous Metabolite
5'-Methylthioadenosine-d₃ is the deuterium labeled 5'-Methylthioadenosine[1]. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2][3][4].

HY-163081

PARP7-IN-17

PARP Cancer

PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-15888A

PTC-209 hydrobromide 5+ Cited Publications	Autophagy	Cancer
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment .

HY-125836

CCR4 antagonist 2	CCR	Endocrinology Cancer
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca ²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-107202

Polyinosinic-polycytidylic acid 10+ Cited Publications Poly(I:C)	Toll-like Receptor (TLR) PKD HSP Bcl-2 Family Interleukin Related	Infection Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .

HY-144274

IDO1-IN-14	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-14 (compound 4a) is a potent IDO1 inhibitor with an IC₅₀ of 396.9 nM. IDO1-IN-14 has cellular IDO1 inhibition (HeLa EC₅₀=3393 nM) .

HY-144273

IDO1-IN-13	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC₅₀ of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC₅₀= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues .

HY-158057

A2AR/A2BR antagonist 1	Adenosine Receptor	Cancer
A_2AR/A_2BR antagonist 1 (compound 7ai) has a dual antagonistic effect on A_2AR/A_2BR, with the IC₅₀ values of 11.2 nM and 6.4 nM for A_2AR and A_2BR, respectively. A_2AR/A_2BR antagonist 1 promotes T cell-mediated cancer cell death .

HY-A0183

Phosphatidylserine Phospholipids, phosphatidylserines; Serine glycerophosphatides
Phosphatidylserine is a conserved anti-inflammatory and immunosuppressive signal that is highly dysregulated in the tumor microenvironment and autoimmune diseases. During apoptosis and cellular stress，the related disrupting enzymes Xkr8 and TMEM16 mediate Phosphatidylserine externalization. Phosphatidylserine externalization produces a "eat me" signal that initiates endocytosis and helps clear the body of apoptotic cells. When pathogens use Phosphatidylserine and apoptotic mimicry to evade host immune responses，targeting Phosphatidylserine strategies can stimulate immune activity .

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases .

HY-N3387

Licoricidin	Apoptosis NF-κB Akt MMP	Inflammation/Immunology Cancer
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

HY-158050

PXB17	c-Fms
PXB17 can inhibit CSF1R (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .

HY-162382

KTC1101	PI3K Akt mTOR	Cancer
KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .

HY-135748A

Poly (I:C):Kanamycin (1:1) (sodium) 10+ Cited Publications	Toll-like Receptor (TLR) Apoptosis	Infection Cancer
Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .

HY-148029

Dazostinag disodium TAK-676	STING	Cancer
Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .

HY-78131

Ibuprofen 10+ Cited Publications (±)-Ibuprofen	COX Apoptosis Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .

HY-78131C

Ibuprofen sodium 10+ Cited Publications (±)-Ibuprofen sodium	COX Apoptosis Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .

HY-78131S3

Ibuprofen-13C6 (±)-Ibuprofen-¹³C₆	Isotope-Labeled Compounds	Cancer
Ibuprofen- ¹³C₆ ((±)-Ibuprofen- ¹³C₆) is a ¹³C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .

HY-126077

MTI-31 LXI-15029	mTOR	Inflammation/Immunology Cancer
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC₅₀ of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16938

5'-Methylthioadenosine 3 Publications Verification 5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Apoptosis Parasite
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .

HY-N3387

Licoricidin	Natural Products Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Glycyrrhiza uralensis Fisch.	Apoptosis NF-κB Akt MMP
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

Cat. No.	Product Name	Chemical Structure

HY-16938S

5'-Methylthioadenosine-13C6

5'-Methylthioadenosine- ¹³C₆ is the ¹³C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].

HY-16938S1

5'-Methylthioadenosine-d3

5'-Methylthioadenosine-d₃ is the deuterium labeled 5'-Methylthioadenosine[1]. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2][3][4].

HY-78131S3

Ibuprofen-13C6

Ibuprofen- ¹³C₆ ((±)-Ibuprofen- ¹³C₆) is a ¹³C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks